Fidelity International
PRME icon

Fidelity International’s Prime Medicine PRME Stock Holding History

Fidelity International’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$425K Hold
115,206
– – ﹤0.01% 933
2026
Q1 		$401K Sell
115,206
-396
-0.3% -$1.51K ﹤0.01% 883
2025
Q4 		$401K Sell
115,602
-727
-0.6% -$3.23K ﹤0.01% 878
2025
Q3 		$644K Sell
116,329
-941
-0.8% -$3.82K ﹤0.01% 812
2025
Q2 		$290K Sell
117,270
-3,747
-3% -$5.78K ﹤0.01% 830
2025
Q1 		$241K Hold
121,017
– – ﹤0.01% 821
2024
Q4 		$353K Sell
121,017
-8,844
-7% -$31K ﹤0.01% 813
2024
Q3 		$503K Sell
129,861
-8,415
-6% -$39K ﹤0.01% 774
2024
Q2 		$711K Hold
138,276
– – ﹤0.01% 736
2024
Q1 		$968K Sell
138,276
-8,666
-6% -$65.7K ﹤0.01% 722
2023
Q4 		$1.3M Sell
146,942
-1,658,616
-92% -$12.8M ﹤0.01% 691
2023
Q3 		$17.2M Hold
1,805,558
– – 0.02% 425
2023
Q2 		$26.5M Hold
1,805,558
– – 0.03% 375
2023
Q1 		$22.2M Hold
1,805,558
– – 0.03% 379
2022
Q4 		$33.5M Buy
+1,805,558
New +$32.6M 0.04% 345

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity International's PRME Position: Q2 2026 in Review

Fidelity International held its Prime Medicine (PRME) position steady in Q2 2026 at 115,206 shares worth $425K. The position accounts for ﹤0.01% of the portfolio, ranked #933.

Fidelity International first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $33.5M in Q4 2022. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Fidelity International held 115,206 shares of Prime Medicine worth $425K as of Q2 2026.
  • Fidelity International left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of Fidelity International's portfolio in Q2 2026, its #933 holding.
  • Fidelity International first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Fidelity International's Prime Medicine position peaked at $33.5M in Q4 2022.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.